UTR Therapeutics Inc. is a Pre-Clinical Stage biotech company with a first-in-class technology that can overwrite any target of interest. We’ve proven this robustly in difficult to treat cancers and are ready to scale into Neurodegenerative and Rare Diseases.
Over 75% of human cancer over expresses c-MYC. UTR Therapeutics Inc. technology also controls HER2 in drug resistant breast cancer, non small cell lung cancer, HER2 mutated lung cancer and in HER2 expressing colorectal cancer. We are also able to control any transcript of interest without causing genome rearrangement
Our mission is to change how we treat cancer
Embrace the diverse backgrounds, skill sets, and value that unique perspectives can provide.
Utilize hiring practices that support diversity, equity and inclusion